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Abstract 
Peroxiredoxin II (Prx II) is known not only to protect
cells from oxidative damage caused by hydrogen per-
oxide (H2O2), but also to endow cancer cells with resis-
tance to both H2O2 and cisplatin and to grant them
radioresistance. In this study, we examined whether
Prx II antisense could enhance cisplatin-induced cell
death. When gastric  cancer cells were transfected with
various concentrations of Prx II antisense plasmid,
pPrxII/AS, and then treated with the same concentra-
tions of cisplatin, Prx II antisense enhanced cisplatin-
induced cell death. The combination index (CI) at all
doses of the combination was below 1, indicating that
Prx II antisense sensitized cisplatin-induced cell death.
This synergism was also observed in the cells trans-
fected with a Prx II antisense oligomer. Our present
results, therefore, suggest that Prx II antisense would
be a very good sensitizer for cisplatin, and that Prx II as
a target for chemosensitizers constitutes a promising
avenue for future research.
Keywords: Prx II, cisplatin, chemosensitizer, antisense,
multidrug resistance
Introduction
Prx II is an antioxidant enzyme that reduces H2O2 and
other reactive oxygen species using thioredoxin as the
immediate electron donor (Chae et al., 1994), and its
peroxidase activity prevents cells from reactive oxygen
species insult (Chae and Rhee, 1999). Prx II is also
involved in the cellular signaling pathways of growth
factors and tumor necrosis factor-α, by virtue of its
regulation of intracellular H2O2 (Kang et al., 1998; Sen,
1998). Six Prx isoforms have been identified which,
based on the amino acid sequences, are generally
divided into two subfamilies; groups I, II, III, and IV with
two conserved cysteines and groups V and VI with one
conserved cysteine (Butterfield et al., 1999). Prx I and
Prx II proteins are known to be located in cytoplasm
(Chae et al., 1999).
Prx overexpression is frequently observed in certain
types of cancer tissues. Three types of Prx (I, II, and III)
have been shown to be overexpressed in the case of
human breast cancer, and it has been suggested that their
overexpressions are related to cancer development or
progression (Noh et al., 2001). The increased expression
of Prx I is also detected in lung cancer, thyroid tumors and
oral cancer, and is suggested to constitute a potential
tumor marker (Yanagawa et al., 1999; Yanagawa et al.,
2000; Chang et al., 2001). Prx II is upregulated by H2O2
and cisplatin treatment, and its increased expression
inhibits the apoptosis induced by cisplatin, thyrotropin,
serum deprivation, ceramide, or etoposide, thereby
rendering tumor cells resistant to some chemotherapeutic
agents (Zhang et al., 1997; Kim et al.,2000; Chung et al.,
2001). We demonstrated earlier that Prx II was involved in
radioresistance (Park et al., 2000). In the present study,
therefore, we explored the possibility as to whether
inhibition of Prx II expression with antisense or drugs
would accelerate cell death induced by anticancer agents.
Materials and Methods
Drug sensitivity assay
Human gastric-carcinoma cells (SNU638), were cultured
at 37oC under 5% CO2 in an RPMI 1640 medium
(GIBCO/BRL, Grand Island, NY), containing 10% heat-
inactivated fetal bovine serum, sodium bicarbonate (2
mg/ml), penicillin (100 units/ml) and streptomycin (100
µg/ml). Exponentially growing SNU638 cells (2 x 105)
were transferred to 60-mm culture dishes, and the cells
were then transfected with various concentrations of the
antisense Prx II expression vector (pPrxII/AS) or with
antisense/sense oligomers combined with a mixture of
cationic liposome (GIBCO/BRL). The cells were added
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process of transfection was then repeated a second
time. The cells were treated with various doses of
cisplatin 16 h after transfection. After 4 days of in-
cubation at 37oC, surviving cells were counted under a
microscope.
Determination of apoptotic cell death 
SNU638 cells (1 x 106) were transferred to 100-mm
culture dishes and the cells were transfected with 0.5
µg/ml of the antisense Prx II expression vector (pPrxII/
AS) along with a mixture of 5 µg of cationic liposome
(GIBCO/BRL), and the process was repeated a second
time. After 16 h, the cells were treated with various
doses of cisplatin, cultured for another 2 days, and then
harvested. They were stained with propidium iodide and
apoptotic cell death was then analyzed by flow
cytometric analysis (FACscan; Becton Dickinson,
Mountain View, CA), according to the manufacturer’s
instruction.
Data analysis
All results are expressed as mean ± standard deviation
(SD). Statistical analysis between each group was
performed by one-way analysis of variance (ANOVA).
Statistical significance was accepted as P < 0.05. The
combined effect of Prx II antisense and cisplatin was
determined by dose-effect analysis, calculated using a
microcomputer (Biosoft, Cambridge, England). A
combination index (CI) value < 1 represents synergy
between Prx II antisense and cisplatin, a CI value > 1
indicates antagonism, and a CI value of 1 means that
the effects of the two agents are additive.
Results
SNU638 cells were transfected with various concen-
trations of plasmid, pPrxII/AS, and then treated with the
same concentrations of cisplatin. After incubation for 4
days, the cells were counted under a microscope. As
shown in Figure 1A, pPrxII/AS itself caused cell death,
which is consistent with our previous results on en-
hanced radiation-induced cell death by pPrxII/AS (Park
et al., 2000). Our previous results also demonstrated that
pPrxII/AS inhibited Prx II expression (Park et al., 2000;
Chung et al., 2001). pPrxII/AS and cisplatin caused 45.1%
and 53.5% cell death, respectively, at a dose of 2 µg,
when used separately. However, combined treatment with
these two agents caused 99.1% of cell death, suggesting
Figure 1. Cisplatin sensitization of SNU638 cells after transfection with an
antisense Prx II expression plasmid (pPrxII/AS). Cells were transfected with
0.25, 0.5, 1, 2, and 4 µg/ml of pPrxII/AS respectively, as described in
Materials and Methods. The cells were then treated with 0.25, 0.5, 1, 2, and
4 µg/ml of cisplatin, respectively. After 4 days, cell survival was measured
by cell counting and same experiments were repeated three times. Panel A:
Survival of cells after treatment with pPrxII/AS ( ) or cisplatin ( ) or
pPrxII/AS + cisplatin (). Panel B: Fa-CI plot. A CI value < 1 represents
synergy between Prx II antisense and cisplatin. Statistical significance
between pPrxII/AS and pPrxII/AS+cisplatin, and between cisplatin and
pPrxII/AS + cisplatin was analyzed. * P < 0.01.
Table 1. Sequences of Prx II antisense oligomers
Name Sequence
AS-1 CAGGTGGGGGCACAGGTGGA
AS-2 TCCGTTAGCCAGCCTAATTG
AS-3 GTTGGGCTTAATCGTGTCAC
AS-4 GTCTGTGTACTGGAAGGCCT
AS-5 CAAATCATTAACAGTGATCT
AS-6 GTAGGCAATGCCCTCATCTG
AS-7 ACGCCGTAATCCTCAGACAA
AS-8 GTCACCAAGCAGGGGGATGT
AS-9 CCAAGCCAGGTGGTTGAACT
AS-10 GCGGAAGTCCTCTGCACGGT
AS-11 GTCCAGAGGGTAGAAAAAGA
AS-12 TTTGAAGGCGCCATCAACCA
AS-13 CGCGCGTTACCGGAGGCCAT
AS-14 AGCTGCGTGGGCAAAGGCTA
 Prx II antisense as a chemosensitizer 275that pPrxII/AS enhanced cisplatin-induced cell death. To
confirm this synergistic effect, a CI plot was drawn.
Figure 1B shows the CI value below 1 at all doses of the
combination, indicating synergism.
In the above experiments, we used the full-length Prx II
antisense. In order to examine whether antisense
oligomers were also able to sensitize cisplatin-induced cell
death, we prepared 14 antisense oligomers, which are
listed in Table 1, and carried out similar experiments.
Figure 2 shows that all 14 antisense oligomers induced
cell death following transfection. Out of the 14 oligomers,
we selected the AS12 oligomer as the best antisense oli-
gomer for inducing cell death, and used it for sensitization
experiments: One µM of AS12 induced~80% cell death.
Treatment of the cells with a Prx II sense oligomer (S12),
which is complimentary to AS12, did not alter cell viability,
compared with the cells transfected with liposome only,
thereby demonstrating that Prx II antisense itself was
responsible for cell death. On the other hand, when
SNU638 cells were transfected with AS12, the higher
the dosage of AS12 in the cells, the greater the cell
death followed (Figure 3A). When the cells were treated
with these two agents together, 82.9% of cell death was
observed, whereas AS12 or cisplatin alone, at a dose of
1.25 µg/ml, caused 50.0% or 42.4% cell death,
respectively, suggesting that the Prx II antisense oli-
gomer also enhanced cisplatin-induced cell death. A CI
plot indicated that at all doses of the combination, except
for the case of 10% inhibition, the CI was below 1, thus
confirming the synergistic effect (Figure 3B). To de-
monstrate the effect of Prx II antisense on apoptosis, the
cells transfected with pPrxII/AS, following treatment with
cisplatin, was examined by flow cytometry. Figure 4 shows
that treatment of the transfected cells with 5 µg/ml of
cisplatin for 48 h induced 32.50% of apoptosis, whereas
26.13% of apoptosis was induced in the cells transfected
with pPrxII/S. These results suggest that Prx II antisense
can be used as a chemosensitizer.
Discussion
Prx II is an isotype of thioredoxin-dependent peroxidase,
which reduces intracellular hydrogen peroxide that are
detrimental to cells (Chae et al., 1994). Prx II was known
to be induced by exogenous H2O2 generated by
thyrotropin, serum deprivation, ceramide, or etoposide,
possibly through eliminating intracellular H2O2 and other
reactive oxygen species (Kim et al., 1997; Zhang et al.,
1997; Kim et al., 2000), that are formed as a result of
cisplatin treatment or radiation exposure (Sodhi and
Gupta, 1986; Park et al., 2000; Leach et al., 2001). We
Figure 3. Synergistic effect of an antisense Prx II oligomer, AS-12,
combined with cisplatin. Cells were transfected with 0.002, 0.01, 0.05, 0.25,
and 1.25 µg/ml of pPrxII/AS, respectively. The cells were then treated with
0.002, 0.01, 0.05, 0.25, and 1.25 µg/ml of cisplatin, respectively. After 4
days, cell survival was measured by cell counting and same experiments
were repeated three times. Panel A: Survival curve of cells after treatment
with pPrxII/AS ( ) or cisplatin ( ) or pPrxII/AS + cisplatin ( ). Panel
B: Fa-CI plot. Statistical significance between pPrxII/AS and pPrxII/
AS+cisplatin, and between cisplatin and pPrxII/AS+cisplatin was analyzed.
*P < 0.01, **P < 0.05.
Figure 2 Cell survival in Prx II antisense oligomers-treated SNU638. The
cells were transfected twice with each 1 mM antisense oligomers and a
sense oligomer as a control. After 4 days, survival curve was determined by
cell counting and same experiments were repeated three times. ASs, cells
transfected with the corresponding antisense oligomers; S12, cells trans-
fected with S12; L, cells transfected with liposome only. Statistical signi-
ficance between a sense oligomer (S12) and each antisense oligomers was
analyzed. *P < 0.01, **P < 0.05.
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directly related to cisplatin resistance, and suggested that
increased activity of Prx II might confer cancer cells with
chemoresistance (Chung et al., 2001) or radioresistance
(Park et al., 2000). This resistance seemed to be derived
from the presence of an increased amount of Prx II,
enabling the elimination of hydrogen peroxide produced
as a consequence of cisplatin or radiation treatment. Cells
resistant to H2O2 were reported to be resistant to cisplatin
(Spitz et al., 1993), and down-regulation by Prx II
antisense sensitized radiation-induced cell death (Park et
al., 2000). Indeed, as shown in the present results, Prx II
antisense effectively enhanced cisplatin-induced cell
death. Even though, in this report, we showed only that
Prx II anti-sense sensitized cisplatin-induced cell death,
we suggest that Prx II antisense could also enhance
other instances of anticancer drug-induced cell death,
especially in the case of anticancer drugs which
generate reactive oxy-gen species. This observation is
consistent with pre-vious results (Zhang et al., 1997)
where Prx II overexpression inhibited apoptosis in Molt-
4 leukemia cells and functioned in a similar manner to
Bcl-2. Also, Prx II overexpression rendered gastric
cancer and ECV304 cells more resistant to
chemotherapeutic drugs (Kang et al., 1998).
Cellular resistance to anticancer drugs and γ-radiation is
one of the difficulties encountered in the effective treat-
ment of numerous cancers. Therefore, the enhancement
of cellular sensitivity toward chemo- or radiation therapy
constitutes an important field of research for improving
cancer treatments. Because blocking the expression of
Prx II disrupts total cellular redox homeostasis and
induces apoptosis (Sato et al., 1995), Prx II could be the
focus of new drugs for use in the treatment of cancer.
Our data, presented herein, strongly suggest that in-
activation of the stress-activated protein Prx II constitutes
a promising approach to the development of improved
cancer treatments, and that inhibitors of Prx II represent
very good anticancer drug candidates, especially in the
role of chemosensitizers or radio-sensitizers.
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